TAK 888 is an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed by Takeda for the treatment of COVID-2019 infections. Hyperimmune globulins are plasma derived-therapies. H-IG will act by concentrating the pathogen-specific antibodies from the plasma obtained from recovered patients or vaccinated donors in the future. Transferring the antibodies to a new patient can help that person’s immune system respond to the infection. Early research is underway in Japan.
As of March 2019, Takeda is in discussions with multiple national health and regulatory agencies and health care partners in the US, Asia, and Europe for the development of TAK 888  .
In April 2020, Biotest, Bio Products Laboratory (BPL), LFB, and Octapharma joined an alliance formed by CSL Behring and Takeda Pharmaceutical to develop a potential plasma-derived therapy for the treatment of COVID-19. The collaboration leads to the development of an unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19. The collaboration will leverage leading-edge expertise and work that the companies already have underway. Experts from the alliance will begin collaborating across key aspects such as plasma collections, clinical trial development and manufacturing. 
Key Development Milestones
As of March 2020, early research is underway for TAK 888 in Japan  .